Matta A, Nader V, Galinier M, Roncalli J. Transplantation of CD34+ cells for myocardial ischemia. World J Transplant 2021; 11(5): 138-146 [PMID: 34046316 DOI: 10.5500/wjt.v11.i5.138]
Corresponding Author of This Article
Jerome Roncalli, MD, PhD, Full Professor, Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, 1 Avenue Jean Poulhès, Toulouse 31059, France. roncalli.j@chu-toulouse.fr
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Transplant. May 18, 2021; 11(5): 138-146 Published online May 18, 2021. doi: 10.5500/wjt.v11.i5.138
Transplantation of CD34+ cells for myocardial ischemia
Anthony Matta, Vanessa Nader, Michel Galinier, Jerome Roncalli
Anthony Matta, Vanessa Nader, Michel Galinier, Jerome Roncalli, Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse 31059, France
Anthony Matta, Faculty of Medicine, Holy Spirit University of Kaslik, Kaslik 00000, Lebanon
Vanessa Nader, Faculty of Pharmacy, Lebanese University, Beirut 961, Lebanon
Author contributions: Matta A contributed to conception, design and writing of the report; Nader V contributed to conception and design of the report; Galinier M revised the paper; Roncalli J contributed to design and writing of the report and provided important intellectual contributions to the study.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jerome Roncalli, MD, PhD, Full Professor, Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, 1 Avenue Jean Poulhès, Toulouse 31059, France. roncalli.j@chu-toulouse.fr
Received: January 29, 2021 Peer-review started: January 29, 2021 First decision: February 25, 2021 Revised: March 1, 2021 Accepted: April 13, 2021 Article in press: April 13, 2021 Published online: May 18, 2021 Processing time: 107 Days and 22.9 Hours
Abstract
CD34+ cells are multipotent hematopoietic stem cells also known as endothelial progenitor cells and are useful in regenerative medicine. Naturally, these cells are mobilized from the bone marrow into peripheral circulation in response to ischemic tissue injury. CD34+ cells are known for their high proliferative and differentiation capacities that play a crucial role in the repair process of myocardial damage. They have an important paracrine activity in secreting factors to stimulate vasculogenesis, reduce endothelial cells and cardiomyocytes apoptosis, remodel extracellular matrix and activate additional progenitor cells. Once they migrate to the target site, they enhance angiogenesis, neovascularization and tissue regeneration. Several trials have demonstrated the safety and efficacy of CD34+ cell therapy in different settings, such as peripheral limb ischemia, stroke and cardiovascular disease. Herein, we review the potential utility of CD34+ cell transplantation in acute myocardial infarction, refractory angina and ischemic heart failure.
Core Tip: CD34+ cells are mobilized from the bone marrow into the peripheral circulation in response to ischemic tissue injury. Once they migrate to the target site, they enhance angiogenesis, neovascularization and tissue regeneration. Safety and efficacy of CD34+ cell transplantation has been investigated in order to limit left ventricular dysfunction after acute myocardial infarction, refractory angina and heart failure.
